268 related articles for article (PubMed ID: 28389531)
41. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
42. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
[TBL] [Abstract][Full Text] [Related]
43. Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors.
Pawlak A; Ziolo E; Fiedorowicz A; Fidyt K; Strzadala L; Kalas W
BMC Cancer; 2016 Nov; 16(1):893. PubMed ID: 27852227
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of HOXA4 and HOXA9 genes promotes self-renewal and contributes to colon cancer stem cell overpopulation.
Bhatlekar S; Viswanathan V; Fields JZ; Boman BM
J Cell Physiol; 2018 Feb; 233(2):727-735. PubMed ID: 28464221
[TBL] [Abstract][Full Text] [Related]
45. Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing
Duabil AJ; Cooper CR; Aldujaily E; Halford SE; Hirschberg S; Katugampola SD; Jones GD
Explor Target Antitumor Ther; 2023; 4(5):1210-1226. PubMed ID: 38214010
[TBL] [Abstract][Full Text] [Related]
46. AA-NAT, MT1 and MT2 Correlates with Cancer Stem-Like Cell Markers in Colorectal Cancer: Study of the Influence of Stage and p53 Status of Tumors.
Casado J; Iñigo-Chaves A; Jiménez-Ruiz SM; Ríos-Arrabal S; Carazo-Gallego Á; González-Puga C; Núñez MI; Ruíz-Extremera Á; Salmerón J; León J
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28604612
[TBL] [Abstract][Full Text] [Related]
47. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.
Li XL; Zhou J; Chen ZR; Chng WJ
World J Gastroenterol; 2015 Jan; 21(1):84-93. PubMed ID: 25574081
[TBL] [Abstract][Full Text] [Related]
48. A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress.
Egger T; Bordignon B; Coquelle A
Sci Rep; 2022 Mar; 12(1):5422. PubMed ID: 35361811
[TBL] [Abstract][Full Text] [Related]
49. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
[TBL] [Abstract][Full Text] [Related]
50. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke WC; Heinemann V
Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
[TBL] [Abstract][Full Text] [Related]
51. CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.
Sarmento LM; Póvoa V; Nascimento R; Real G; Antunes I; Martins LR; Moita C; Alves PM; Abecasis M; Moita LF; Parkhouse RM; Meijerink JP; Barata JT
Oncogene; 2015 Jun; 34(23):2978-90. PubMed ID: 25132270
[TBL] [Abstract][Full Text] [Related]
52. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
53. Combination treatment with flavonoid morin and telomerase inhibitor MST‑312 reduces cancer stem cell traits by targeting STAT3 and telomerase.
Chung SS; Oliva B; Dwabe S; Vadgama JV
Int J Oncol; 2016 Aug; 49(2):487-98. PubMed ID: 27279256
[TBL] [Abstract][Full Text] [Related]
54. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Ogino S; Meyerhardt JA; Cantor M; Brahmandam M; Clark JW; Namgyal C; Kawasaki T; Kinsella K; Michelini AL; Enzinger PC; Kulke MH; Ryan DP; Loda M; Fuchs CS
Clin Cancer Res; 2005 Sep; 11(18):6650-6. PubMed ID: 16166444
[TBL] [Abstract][Full Text] [Related]
55. Targeting the replication stress response in cancer.
Forment JV; O'Connor MJ
Pharmacol Ther; 2018 Aug; 188():155-167. PubMed ID: 29580942
[TBL] [Abstract][Full Text] [Related]
56. Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells.
Park SY; Kim JH; Choi JH; Lee CJ; Lee WJ; Park S; Park ZY; Baek JH; Nam JS
Clin Transl Med; 2021 Nov; 11(11):e552. PubMed ID: 34841679
[TBL] [Abstract][Full Text] [Related]
57. Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation.
Yu X; Li W; Liu H; Deng Q; Wang X; Hu H; Xu-Monette ZY; Xiong W; Lu Z; Young KH; Wang W; Li Y
J Hematol Oncol; 2020 May; 13(1):40. PubMed ID: 32357935
[TBL] [Abstract][Full Text] [Related]
58. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model.
Campagne O; Davis A; Maharaj AR; Zhong B; Stripay J; Farmer D; Roussel MF; Stewart CF
Eur J Pharm Sci; 2020 Jan; 142():105106. PubMed ID: 31669383
[TBL] [Abstract][Full Text] [Related]
59. Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies.
Frank MH; Wilson BJ; Gold JS; Frank NY
Gastroenterology; 2021 May; 160(6):1947-1960. PubMed ID: 33617889
[TBL] [Abstract][Full Text] [Related]
60. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.
Li H; Zhang J; Tong JHM; Chan AWH; Yu J; Kang W; To KF
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
